Catalog19 refs
PNC-27
BioregulatorsAnti-Cancer PeptideOtherResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Circulation
Overview
Experimental anti-cancer peptide created by a supercomputer at SUNY Downstate Medical Center in 2000. Contains an HDM-2 binding domain from p53 (residues 12-26) linked to a cell-penetrating domain. Selectively kills cancer cells by binding to HDM-2 (MDM2) expressed on cancer cell membranes, forming pores that cause cell necrosis. Has no effect on normal cells because healthy cells do not express HDM-2 on their membranes. Also enters cancer cells and disrupts mitochondrial membranes. Also known as: PNC27.
Primary Uses
Cancer cell apoptosis induction
Bcl-2 family protein inhibition
p53-mutant cancer models
Mitochondrial apoptosis research
Leukemia cell necrosis induction
Cervical cancer cell killing
Early cancer diagnosis (conjugated with SPIONs)
Pancreatic cancer treatment
Breast cancer treatment
Leukemia treatment
Melanoma treatment
HDM-2 expressing tumor treatment
Cancer-selective therapy research
Tumor selectivity research
Anti-cancer research
Kills cancer cells in vitro while sparing normal cells
Protocol Reference
Dose
Preclinical research only
Frequency
N/A
Half-life
Not Well Characterized In Vivo
Route
Injection
Evidence
Preclinical / Emerging / In vitro and ex vivo (disputed)
Research References· 19
Annals of Clinical & Laboratory Science 2015 \- Ex vivo efficacy in patient-derived ovarian cancer ↗
https://pubmed.ncbi.nlm.nih.gov/20182728/
PubMedPMID 20182728- [https://www.mdpi.com/2227-9059/10/5/945](https://www.mdpi.com/2227-9059/10/5/945)
Research Models
micein vitroanimals
Also in Bioregulators